印度霍乱预防:口服霍乱疫苗政策讨论的系统综述
本文通过系统综述综合印度霍乱疾病负担、分布、免疫规划项目问题与竞争性优先事项。分析显示印度霍乱负担估计受限于单一研究外推,各区脆弱性异质,疫情报告提示部分人群更易感。口服霍乱疫苗可作为多组分预防策略之一,但奥里萨邦公共卫生系统接种第二剂仅46%,单剂策略证据积累。
要点
- 印度霍乱负担估计受限于单一研究外推,各区脆弱性异质。
- 奥里萨邦公共卫生系统接种第二剂仅46%,第一剂61%。
- 口服霍乱疫苗可作为多组分预防策略之一,需关注公平性。
核心结论
- 口服霍乱疫苗可作为印度霍乱多组分预防策略的组成部分,但不能替代安全水、环境卫生与个人卫生投入及健康服务公平性改善。
研究设计与样本
- 系统综述,纳入同行评议文章及印度政府综合疾病监测规划数据,围绕疾病负担与分布、潜在影响、项目问题及竞争性优先事项进行综合。
主要发现
- 印度霍乱负担估计受限于从加尔各答单一发病研究外推。
- 685个印度地区对霍乱脆弱性存在异质性。
- 疫情报告分析显示部分定居点和亚人群更易感腹泻或霍乱。
- 基础设施故障导致饮用水污染及行为问题值得关注。
- 奥里萨邦公共卫生系统接种口服霍乱疫苗时,目标人群第一剂覆盖61%,第二剂仅46%。
关键数值与推荐
- 奥里萨邦公共卫生系统接种口服霍乱疫苗:第一剂覆盖61%,第二剂覆盖46%。
- 全球证据积累支持单剂口服霍乱疫苗策略,所用疫苗与印度获批疫苗相同。
临床怎么用
- 在霍乱脆弱地区可考虑将口服霍乱疫苗纳入多组分预防,同时优先投入安全水、环境卫生与个人卫生并改善脆弱人群健康服务公平性。
- 实施中需关注第二剂低接种率问题,并参考单剂策略证据及印度疫情短持续特点进行务实决策。
局限性
- 印度霍乱负担估计受限于从加尔各答单一发病研究外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Development of oral cholera vaccines (OCVs) experienced exciting times over the last two decades. A two-dose OCV, found efficacious through field trials, has obtained license for use in India. However, the current policy discussion revolves around 'to use or not to use' this vaccine covering entire population in the country, which has its own cost implications. We conducted a systematic review to address this conundrum. The disease burden and distribution, potential impact, programmatic issues, and competing priorities were kept in consideration. Peer reviewed articles and 'Integrated Disease Surveillance Program' data, generated by Government of India, were accessed. Our synthesis highlights that cholera burden estimates for India have been hamstrung by their extrapolation from a single incidence study conducted in Kolkata. Heterogeneity of 685 Indian districts regarding vulnerability to cholera is also obvious. Analysis of outbreak reports indicated that some settlements and sub-populations were more vulnerable to diarrhea/cholera than others. Infrastructure failure leading to contamination of drinking water and behavioral issues were of concern. Investment in safe water, sanitation and hygiene (WASH) and addressing inequity of health services pertaining to vulnerable population groups are the needs of the hour. OCV could play an important role as one of the elements in such multi-component cholera prevention effort. OCV administration through public health system in Odisha identified logistic challenges, with low uptake of the second dose at 46%, while 61% of the target population received the first dose. We identified accumulating global evidence on the advantage and efficacy of single-dose based approach, where the same OCV, as licensed in India, was used. The short-lasting nature of cholera outbreaks in India also argue in favor of such pragmatism. Failure to implement multi-component prevention strategy today runs the risk of perpetuating inequity, recurring cholera outbreaks in future, and its retinue of costs.
引用
- Panda S, Chatterjee P, Deb A, et al. Preventing cholera in India: Synthesizing evidences through a systematic review for policy discussion on the use of oral cholera vaccine. Vaccine. 2019. PMID: 31405636. doi:10.1016/j.vaccine.2019.07.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。